{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107313","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.020170+00:00","generated_at":"2026-05-17T14:47:40.857463+00:00","sec_items":["2.02","9.01","2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028","bullets":["Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.","Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).","Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.","ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107313","json":"https://secwatch.observer/filing/0000950170-25-107313.json","markdown":"https://secwatch.observer/filing/0000950170-25-107313.md","text":"https://secwatch.observer/filing/0000950170-25-107313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/oric-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:47:40.857463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77e22eb13a44b8dea76f81ee536f77410ce51636","claim":"Oric Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.9 million affecting discovery research group (approximately 20% workforce reduction).","evidence_excerpt":"On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of its two lead clinical programs, ORIC-944 and ORIC-114. This initiative will result in a substantial decrease in preclinical research, primarily from the elimination of the Company’s discovery research group. This will result in an approximately 20% workforce reduction and the Company expects to incur a one-time cost of approximately $1.9 million primarily related to termination benefits, including severance and healthcare-related benefits.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/0000950170-25-107313-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.9 million"},{"label":"Affected area","value":"discovery research group"},{"label":"Headcount","value":"approximately 20% workforce reduction"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}